This website sells research peptides exclusively for scientific and laboratory research purposes.
Do you confirm you are 18+ and accessing this site for legitimate research purposes?
Semaglutide targets only the GLP-1 receptor, while Tirzepatide acts on both GIP and GLP-1 receptors simultaneously. This fundamental difference in receptor targeting creates distinct downstream signalling profiles. Semaglutide research has examined GLP-1 receptor activation, incretin response, appetite suppression via hypothalamic pathways and pancreatic beta cell effects. Tirzepatide research examines the additive contribution of GIP receptor co-activation alongside GLP-1 signalling, with studies exploring whether dual agonism produces superior metabolic outcomes. Published clinical research in the SURMOUNT and SUSTAIN trial series has generated extensive comparative data. Research continues to examine the differential downstream effects of GIP versus GLP-1 receptor activation and the molecular basis of observed differences between single and dual incretin approaches in metabolic research models.
